Work limitations in the outcome assessment of rheumatoid arthritis.

Johanna M W Hazes, Goedele A Geuskens and Alex Burdorf

J Rheumatol 2005;32;980-982
http://www.jrheum.org/content/32/6/980.citation

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Work Limitations in the Outcome Assessment of Rheumatoid Arthritis

The adverse consequences of rheumatoid arthritis (RA), particularly in clinical intervention studies, are traditionally assessed by measuring disease activity, radiographic damage, and loss of function. These outcome measures capture 2 of the 3 domains of the World Health Organization-International Classification of Functioning, Disability, and Health (WHO-ICF) framework, i.e., body functions and structures and activities (Figure 1)\(^1\). The third domain, participation, is increasingly recognized as an important outcome of RA that should be assessed in all outcome and intervention studies in arthritis patients. In OMERACT 7 (Outcome Measures in Rheumatology Clinical Trials) the need for measurement of participation restrictions, in particular work participation, was recognized, although the lack of appropriate and well researched instruments prohibited work participation being included into the core set instruments for arthritis trials.

Various studies have shown that patients with RA are at increased risk to terminate paid employment and to become permanently work disabled\(^2\). The article by Walker, et al in this issue of The Journal\(^3\) adds to our understanding that employed patients with RA may already experience considerable work restrictions that will hamper their ability to perform their work in a productive fashion.

WORK PARTICIPATION AND COST OF ILLNESS

Restriction in work participation strongly represents (indirect) costs of illness, a domain not described in the ICF framework. With powerful but expensive new biological therapies and combination therapies with conventional disease modifying antirheumatic drugs (DMARD), cost-effectiveness outcomes in clinical trials have become mandatory. A recent study showed that patients receiving combination DMARD therapy had a significantly lower number of work disability days after 5 year followup than patients with single DMARD therapy\(^4\). Prompt induction of remission appeared to be the most important determinant for retaining work capacity\(^5\).

Work capacity is primarily assessed by absenteeism (days of sick leave) or work status (work disability). In particular, work status is a rather crude measure that is also dependent on many socioeconomic determinants. Moreover, RA patients who do go to work may experience decreased productivity due to their health problems. The phenomenon where workers turn up at work despite health problems is referred to as sickness presenteeism. The article by Walker, et al in this issue shows that there are considerable work restrictions for those RA patients who work\(^3\), even though RA patients already make major adaptations to maintain employment\(^6\). The study lacks a control group, but earlier work by Lerner, et al provides control data showing a similar trend of work restrictions in a RA population\(^7\). These restrictions translate into loss of productivity, a measure that is often included in the cost-effectiveness analysis of new treatment regimes.

---

See  Work limitations among working persons with RA, page 1006
MEASURING PRODUCTIVITY

Productivity losses can be looked at from the perspective of the patient, i.e., the employee with RA, and from that of the employer. The employee perspective mainly represents absence from work and reduced productivity due to RA. The costs incurred by the employer to maintain productivity also include compensation mechanisms, such as colleagues or temporary workers taking over, productivity losses due to loss in specific knowledge or team production, and extra effort concerning the logistics to replace the partially absent employee. Both perspectives need different instruments and serve different purposes. The Work Limitation Questionnaire (WLQ) is intended to capture the patient’s perspective, measuring the degree to which employed individuals experience limitations on the job due to health problems and the magnitude of the health-related productivity loss. The WLQ includes several items that emphasize activities rather than participation. The overlap of activity limitations and participation restrictions can be confusing and has led to the conclusion by Walker, et al. that the WLQ does not detect functional limitations in RA as well as the Health Assessment Questionnaire (HAQ) or the Medical Outcome Study Short Form-36 (SF-36). The WLQ measures both limitation of activities and restriction of participation; however, it is the restriction of participation that makes the WLQ a promising tool.

Participation is indeed strongly influenced by activity limitation and by body function and structure (Figure 1). It is therefore reassuring that good correlations were found between the WLQ and SF-36, HAQ, pain, and fatigue. Since participation includes many activities, it was recently proposed to combine activities and participation in one comprehensive RA core set. The combination of activities and participation in one core set prohibited the chance to identify work participation in a separate domain. This is particularly important because absenteeism and presenteeism have strong links to health related costs.

TOOLS FOR MEASURING PRODUCTIVITY

There are several instruments to measure presenteeism and productivity. The WLQ has been validated with objective work productivity data, and work productivity was found to be impaired both in RA and in osteoarthritis. The study by Walker, et al. showed that an instrument measuring work performance can show extra benefits of, for example, biological therapies, with respect to their cost-effectiveness. The WLQ may also be an effective assessment tool in psychoeducational interventions, which are not very effective when measured with the conventional outcome measures such as disease activity, damage, and the HAQ. In addition to interventions to alter the disease process, adaptations to change the workplace can positively influence the capabilities of patients with RA to perform their work effectively. Thus, an outcome measure for presenteeism and productivity should be sensitive for both medical and workplace intervention trials. Hopefully, research in the near future will guide us to choose an instrument that will enable us to comprehensively assess (cost-) effectiveness of arthritis management.

HOW CAN WE USE PRODUCTIVITY ASSESSMENT?

Participation, particularly work participation, not only depends on health-related problems, but is also strongly associated with socioeconomic and work-related factors. Education and personal background as well as the disease itself determine the patient’s decision whether to engage in paid employment with a particular job. Presenteeism may therefore not be a good primary health-related outcome measure in long-term inception cohorts. For intervention studies, however, reduced productivity due to RA is a very useful tool to show important changes for the patient as well as its consequences for health-related cost. In particular, the good correlation of the WLQ with fatigue raises the hope that an instrument measuring work performance can show extra benefits of, for example, biological therapies, with respect to their cost-effectiveness. The WLQ may also be an effective assessment tool in psychoeducational interventions, which are not very effective when measured with the conventional outcome measures such as disease activity, damage, and the HAQ. In addition to interventions to alter the disease process, adaptations to change the workplace can positively influence the capabilities of patients with RA to perform their work effectively. Thus, an outcome measure for presenteeism and productivity should be sensitive for both medical and workplace intervention trials. Hopefully, research in the near future will guide us to choose an instrument that will enable us to comprehensively assess (cost-) effectiveness of arthritis management.

JOHANNA M.W. HAZES, MD PhD, Professor of Rheumatology, Department of Rheumatology; GOEDELE A. GEUSKENS, PhD Student, Department of Rheumatology and Department of Public Health; ALEX BURDORF, PhD, Associate Professor in Occupational Health, Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
REFERENCES